Back to results
US 2004/0082787 A1Published application
Chemical compounds
AssigneeLilly ICOS LLC
InventorsMark W Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan, Romain Luc Marie Gosmini, Lisa M Schultze
Life of this patent
Estimating the term…
Abstract
Compounds of general structural formula (I), and use of the compounds or salts or solvates thereof as therapeutic agents, are disclosed. 1
Claims23
A compound having a formula
- 42
- wherein R0, independently, is selected from the group consisting of halo, C1-6alkyl, aryl, heteroaryl, C3-8cycloalkyl, C3-8heterocycloalkyl, C3-8cycloalkylQ, C(═O)Rb, OC(═O)Rb, C(═O)ORb, C1-4alkyleneNRbRc, C1-4alkyleneHet, C1-4alkyleneC(═O)ORb, C(═O) RbSO2Rd, C(═O)C1-4alkyleneHet, C(═O)NRbRc, C(═O)NRbRd, C(═O)NRbC1-4alkyleneORc, C(═O)NRbC1-4alkyleneHet, ORb, OC1-4alkyleneC(═O)ORb, OC1-4alkyleneNRbRc, OC1-4alkyleneHet, OC1-4alkyleneORb, OC1-4alkyleneNRbC(═O)ORc, NRbRc, NRbC1-4alkyleneNRbRc, NRbC(═O)RC, NRbC(═O)NRbRc, N(SO2C1-4alkyl)2, NRb(SO2C1-4alkyl), nitro, trifluoromethyl, trifluoromethoxy, cyano, SO2NRbRc, SO2Rb, SORb, SRb, and OSO2CF3;
- R1 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, an optionally substituted C3-8cycloalkyl ring, an optionally substituted C3-8heterocycloalkyl ring, an optionally substituted bicyclic ring
- 43
- wherein the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one to three heteroatoms selected from oxygen, sulfur, and nitrogen, hydrogen, C1-6alkyl, arylC1-3alkyl, C1-3alkenylaryl, haloC1-6alkyl, C1-4alkyleneC(═O)ORb, C1-4alkyleneC(═O)NRbRc, C3-8cycloalkyl, C3-8cycloalkenyl, C3-8heterocycloalkenyl, C1-4alkyleneHet, C1-4alkyleneQRb, C2-6alkenyleneQRb, C1-4alkyleneQC1-4alkyleneQRb,
- 44
- and a spiro substituent having the structure
- 45
- R2 and R4, independently, are selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, arylC1-3alkyl, C1-3alkylenearyl, C1-3alkyleneHet, C3-8cycloalkyl, and C3-8heterocycloalkyl;
- R3 is selected from the group consisting of hydrogen, C1-6alkyl, C3-8cycloalkyl, C3-8heterocycloalkyl, C2-6alkenyl, C1-3alkylenearyl, arylC1-3alkyl, C(═O)Rb, aryl, heteroaryl, C(═O)Rb, C(═O)NRcRc, C(═O)NRbRd, C(═S)NRbRc, C(═S)NRbRd, SO2Rb, SO2NRbRc, S(═O) Rb, S(═O)NRbRc, C(═O)NRbC1-4alkyleneORb, C(═O)NRbC1-4-alkyleneHet, C(═O)C1-4alkylenearyl, C(═O)C1-4alkyleneheteroaryl, C1-4alkylenearyl substituted with one or more of SO2NRbRc, NRbRc, C(═O)ORb, NRbSO2CF3, CN, NO2, C(═O)Rb, ORb, C1-4alkyleneNRbRc, and OC1-4alkyleneNRbRc, C1-4alkyleneheteroaryl, C1-4alkyleneHet, C1-4alkyleneC(═O)C1-4alkylenearyl, C1-4alkyleneC(═O)C1-4alkyleneheteroaryl, C1-4alkyleneC(═O)Het, C1-4alkyleneC(═O)NRbRc, C1-4alkyleneORb, C1-4alkyleneNRbC (═O) Rb, C1-4alkyleneOC1-4alkyleneORb, C1-4alkyleneNRbRc, C1-4alkyleneC(═O)ORb, and C1-4alkyleneOC1-4alkyleneC(═O)ORb;
- X and Y, independently, are selected from the group consisting of C(═O), SO, SO2, C(═S), C(Ra)2, and C═C(Ra)2;
- Z is O, X, or C (Ra) 2′ or Z is NRd when X or Y is SO, SO2, C(═S), C(Ra)2 or C═C(Ra)2;
- Ra, independently, is selected from the group consisting of hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, aryl, heteroaryl, arylC1-3alkyl, C1-3alkylenearyl, C(═O)ORb, C(═O)NRbRd, C1-4alkyleneNRbRc, halo, NO2, CF3, CF3O, ORb, OC(═O)Rb, OC1-4alkyleneC(═O)ORb, C1-4alkyleneOC1-4alkyleneC(═O)ORb, C(═O)NRbSO2Rd, C(═O)C1-4alkyleneHet, C2-6alkenyleneNRbRc, C(═O)NRaC1-4alkyleneORc, C(═O)NRbC1-4alkyleneHet, OC2-4alkyleneNRbRc, OC1-4alkyleneCH(ORb)CH2NRbRc, OC2-4alkyleneORb, OC2-4alkyleneNRbC(═O)ORc, NRbRc, NRbC1-4alkyleneNRbRc, NRbC(═O)Rc, NRbC(═O)NRbRc, N(SO2C1-4alkyl)2, NRb(SO2C1-4alkyl), SO2NRbRc, OSO2trifluoromethyl, C(═O)Rb, C1-3alkyleneORb, CN, and C1-6alkyleneC(═O)ORb;
- Rb is selected from the group consisting of hydrogen, C1-6alkyl, aryl, arylC1-3alkyl, C1-3alkylenearyl, heteroaryl, heteroarylC1-3alkyl, and C1-3alkyleneheteroaryl;
- Rc is selected from the group consisting of hydrogen, C1-6alkyl, C3-8cycloalkyl, C1-3alkyleneN(Rb)2, aryl, arylC1-3alkyl, C1-3alkylenearyl, and heteroaryl;
- Rd is selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, arylC1-3alkyl, heteroarylC1-3alkyl, C1-3alkyleneN(Ra)2, C1-6alkylenearyl, C1-6alkyleneHet, haloC1-6alkyl, C3-8cycloalkyl, C3-8heterocycloalkyl, C1-3alkyleneHet, C1-3alkyleneheteroaryl, C1-6alkyleneC(═O)ORa, and C1-3alkyleneC3-8heterocycloalkyl;
- or Rb and Rd are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;
- Re is null or is selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, arylC1-3alkyl, heteroarylC1-3alkyl, C1-3alkylenearyl, and C1-3alkyleneheteroaryl;
- Q is O, S, or NRb;
- B is O, S, or NRe;
- C is O, S, or NRb;
- D is CRb or N;
- E is CRb, C (Ra)2, or NRe;
- Het represents a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C1-4alkyl or C(═O)ORb;
- q is 0, 1, 2, 3, or 4;
- and
- pharmaceutically acceptable salts and hydrates thereof.
24 more elements
A compound selected from the group consisting of
- 53 54 55 56
- and pharmaceutically acceptable salts and solvates thereof.
Dependencies are inferred from the claim text.